# Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis

> **NCT03616821** · PHASE2 · TERMINATED · sponsor: **AstraZeneca** · enrollment: 242 (actual)

## Conditions studied

- Ulcerative Colitis
- IBD

## Interventions

- **DRUG:** Brazikumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03616821
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-08-07
- **Primary completion:** 2023-10-23
- **Final completion:** 2023-10-23
- **Target enrollment:** 242 (ACTUAL)
- **Why stopped:** Strategic decision to discontinue the development of brazikumab in inflammatory bowel disease.
- **Last updated:** 2023-11-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03616821

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03616821, "Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03616821. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*